[go: up one dir, main page]

SI2287305T2 - Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina) - Google Patents

Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina) Download PDF

Info

Publication number
SI2287305T2
SI2287305T2 SI200332420T SI200332420T SI2287305T2 SI 2287305 T2 SI2287305 T2 SI 2287305T2 SI 200332420 T SI200332420 T SI 200332420T SI 200332420 T SI200332420 T SI 200332420T SI 2287305 T2 SI2287305 T2 SI 2287305T2
Authority
SI
Slovenia
Prior art keywords
nucleic acid
nucleotides
sina
pyrimidine nucleotides
acid molecule
Prior art date
Application number
SI200332420T
Other languages
English (en)
Other versions
SI2287305T1 (sl
Inventor
James Mcswiggen
Leonid Beigelman
Bharat Chowrira
Pamela Pavco
Kathy Fosnaugh
Sharon Jamison
Nassim Usman
James Thompson
Original Assignee
Sirna Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43446817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2287305(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirna Therapeutics, Inc. filed Critical Sirna Therapeutics, Inc.
Publication of SI2287305T1 publication Critical patent/SI2287305T1/sl
Publication of SI2287305T2 publication Critical patent/SI2287305T2/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/332Abasic residue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity
    • C12N2320/51Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)

Claims (24)

  1. Z RNA-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (siNA) Patentni zahtevki
    1. Kemijsko spremenjena molekula sintetične male interferenčne nukleinske kisline (siNA), ki je sposobna znižati nivo izražanja tarčnega gena v celicah z RNA-interferenco (RNAi), pri čemer siNA obsega: (a) smiselno verigo in protismiselno verigo; (b) vsaka veriga molekule nukleinske kisline je neodvisno dolga od 18 do 24 nukleotidov in siNA dupleks obsega od 17 do 23 baznih parov; (c) 5, 6, 7, 8, 9, 10 ali več pirimidinskih nukleotidov smiselne verige in/ali 5, 6, 7, 8, 9, 10 ali več pirimidinskih nukleotidov protismiselne verige je kemijsko spremenjenih z nukleotidi 2’-deoksi, 2’-0-metil in/ali 2’-deoksi-2’-fluoro; in (d) ena ali več fosforotioatnih internukleotidnih vezi in molekula terminalna kape (ang. cap molecule) na 3’-koncu, 5’-koncu ali na 3’-koncu in 5’-koncu je prisotnih v isti ali različni verigi od siNA pri čemer molekula siNA obsega dva ločena oligonukleotidna fragmenta, pri čemer en fragment obsega smiselno regijo in drugi fragment obsega protismiselno regijo, in pri čemer fragment, ki obsega smiselno regijo, vključuje del terminalne kape na 5’-koncu, 3’-koncu ali tako na 5’-koncu kot tudi na 3’-koncu.
  2. 2. Molekula siNA po zahtevku 1, pri čemer so purinski nukleotidi v smiselni regiji 2’-deoksi purinski nukleotidi in pri čemer so pirimidinski nukleotidi v smiselni regiji 2’-deoksi-2’-fluoro pirimidinski nukleotidi.
  3. 3. Molekula siNA po zahtevku 1, pri čemer so pirimidinski nukleotidi v protismiselni regiji 2’-deoksi-2’-fluoro pirimidinski nukleotidi in pri čemer so purinski nukleotidi v protismiselni regiji 2’-0-metil purinski nukleotidi.
  4. 4. Molekula siNA po zahtevku 1, pri čemer so purinski nukleotidi, ki so prisotni v protismiselni regiji, 2’-deoksi purinski nukleotidi, in pri čemer so pirimidinski nukleotidi, ki so prisotni v protismiselni regiji, 2’-deoksi-2’-fluoro pirimidinski nukleotidi.
  5. 5. Molekula siNA po katerem koli od zahtevkov 1, 3 in 4, pri čemer protismiselna regija obsega fosforotioatno internukleotidno vez pri 3’-koncu protismiselne regije.
  6. 6. Molekula siNA po zahtevku 1, pri čemer vsak od dveh fragmentov molekule siNA obsega 21 nukleotidov.
  7. 7. Molekula siNA po zahtevku 1, pri čemer 19 nukleotidov vsakega fragmenta molekule siNA tvori bazne pare s komplementarnimi nukleotidi drugega fragmenta molekule siNA in pri čemer dva 3’-terminalna nukleotida vsakega fragmenta molekule siNA ne tvorita baznih parov z nukleotidi drugega fragmenta molekule siNA.
  8. 8. Molekula siNA po zahtevku 1, pri čemer 21 nukleotidov protismiselne regije tvori bazne pare z nukleotidnim zaporedjem RNA, ki kodira tarčni gen ali njegov del.
  9. 9. Molekula siNA po zahtevku 1, pri čemer so purinski nukleotidi v smiselni regiji purinski ribonukleotidi in pri čemer so pirimidinski nukleotidi v smiselni regiji 2’-deoksi-2’-fluoro pirimidinski nukleotidi in pri čemer smiselni fragment vključuje del terminalne kape pri 5’-koncu in 3’-koncu.
  10. 10. Molekula siNA po zahtevku 1, pri čemer so purinski nukleotidi v smiselni regiji purinski ribonukleotidi in pri čemer so pirimidinski nukleotidi v smiselni regiji 2’-0-metil pirimidinski nukleotidi in pri čemer smiselni fragment vključuje del terminalne kape pri 5’-koncu in 3’-koncu.
  11. 11. Molekula nukleinske kisline po zahtevku 1, pri čemer 2’-deoksi pirimidinski nukleotidi predstavljajo 5, 6, 7, 8, 9, 10 ali več pirimidinskih nukleotidov v smiselni verigi.
  12. 12. Molekula nukleinske kisline po zahtevku 1, pri čemer 2’-0-metil pirimidinski nukleotidi predstavljajo 5, 6, 7, 8, 9, 10 ali več pirimidinskih nukleotidov v smiselni verigi.
  13. 13. Molekula nukleinske kisline po zahtevku 1, pri čemer 2’-deoksi-2’-fluoro pirimidinski nukleotidi predstavljajo 5, 6, 7, 8, 9, 10 ali več pirimidinskih nukleotidov v smiselni verigi.
  14. 14. Molekula nukleinske kisline po zahtevku 1, pri čemer 2’-0-metil pirimidinski nukleotidi predstavljajo 5, 6, 7, 8, 9, 10 ali več pirimidinskih nukleotidov v smiselni verigi.
  15. 15. Molekula nukleinske kisline po zahtevku 1, pri čemer 2’-deoksi-2’-fluoro pirimidinski nukleotidi predstavljajo 5, 6, 7, 8, 9,10 ali več pirimidinskih nukleotidov v smiselni verigi.
  16. 16. Molekula nukleinske kisline po katerem koli od predhodnih zahtevkov, pri čemer je del terminalne kape invertiran deoksi abazični del.
  17. 17. Molekula nukleinske kisline po katerem koli od predhodnih zahtevkov, ki obsega 1, 2, 3, 4, 5, 6, 7, 8, 9 ali 10 fosforotioatnih internukleotidnih vezi.
  18. 18. Molekula nukleinske kisline po katerem koli od predhodnih zahtevkov, pri čemer molekula nukleinske kisline obsega ribonukleotide.
  19. 19. Molekula nukleinske kisline po katerem koli od predhodnih zahtevkov, pri čemer je tarčna RNA zaporedje sesalske RNA.
  20. 20. Molekula nukleinske kisline po katerem koli od predhodnih zahtevkov, pri čemer je tarčna RNA zaporedje človeške RNA.
  21. 21. Molekula nukleinske kisline po zahtevku 20, pri čemer zaporedje človeške RNA obsega zaporedje človeškega VEGFr-1, VEGFr-2, HER1, HER2, HER3, HER4, TERT, telomerazne RNA, NFkappaB, Re1-A, NOGO, NOGOr, RAS, RAF, CD20, METAP2, CLCA1, fosfolambana ali PTP1B.
  22. 22. Molekula nukleinske kisline po katerem koli od zahtevkov od 1 do 18, pri čemer je tarčna RNA zaporedje virusne RNA.
  23. 23. Molekula nukleinske kisline po zahtevku 22, pri čemer zaporedje virusne RNA obsega zaporedje HBV, HCV, HIV-1, HIV-2, WNV, CMV, RSV, virusa influenze, rinovirusa, papilomavirusa, HSV ali HTLV.
  24. 24. Sestavek, ki obsega molekulo nukleinske kisline po katerem koli od predhodnih zahtevkov, in farmacevtsko sprejemljiv nosilec ali razredčilo.
SI200332420T 2002-02-20 2003-02-20 Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina) SI2287305T2 (sl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35858002P 2002-02-20 2002-02-20
US36312402P 2002-03-11 2002-03-11
US38678202P 2002-06-06 2002-06-06
US40678402P 2002-08-29 2002-08-29
US40837802P 2002-09-05 2002-09-05
US40929302P 2002-09-09 2002-09-09
US44012903P 2003-01-15 2003-01-15
EP10008929.1A EP2287305B2 (en) 2002-02-20 2003-02-20 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)

Publications (2)

Publication Number Publication Date
SI2287305T1 SI2287305T1 (sl) 2015-05-29
SI2287305T2 true SI2287305T2 (sl) 2018-03-30

Family

ID=43446817

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200332420T SI2287305T2 (sl) 2002-02-20 2003-02-20 Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina)
SI200332566T SI2902406T1 (sl) 2002-02-20 2003-02-20 Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200332566T SI2902406T1 (sl) 2002-02-20 2003-02-20 Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina)

Country Status (14)

Country Link
US (2) US20090023676A1 (sl)
EP (18) EP1432724A4 (sl)
JP (6) JP2005524393A (sl)
AT (1) ATE479774T1 (sl)
AU (12) AU2003207708A1 (sl)
CA (3) CA2476112A1 (sl)
CY (2) CY1117168T1 (sl)
DK (4) DK2902406T3 (sl)
ES (3) ES2534045T5 (sl)
GB (2) GB2396616B (sl)
HU (1) HUE036869T2 (sl)
PT (2) PT2287305E (sl)
SI (2) SI2287305T2 (sl)
WO (9) WO2003072704A2 (sl)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050171040A1 (en) * 2001-05-18 2005-08-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050261219A1 (en) * 2001-05-18 2005-11-24 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
GB0212303D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
GB0212302D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Method of selecting targets for gene silencing by RNA interference
SI2258847T1 (sl) 2002-08-05 2017-08-31 Silence Therapeutics Gmbh Nadaljnje nove oblike molekul interferenčne RNA
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
WO2004045543A2 (en) 2002-11-14 2004-06-03 Dharmacon, Inc. Functional and hyperfunctional sirna
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
WO2004063331A2 (en) * 2003-01-03 2004-07-29 Gencia Corporation SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
EP1592412A1 (en) * 2003-01-31 2005-11-09 Novartis AG Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
EP3450559A1 (en) 2003-03-07 2019-03-06 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
CA2488224A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
PT1629088E (pt) 2003-05-30 2012-04-10 Agensys Inc Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas
US7541442B2 (en) 2003-05-30 2009-06-02 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
BRPI0413146A (pt) 2003-08-28 2006-10-03 Novartis Ag dúplex rna interferindo tendo extremidades-embotadas e modificações-3
WO2005045035A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1526177A1 (en) 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
US7476729B2 (en) 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005047504A1 (en) * 2003-11-07 2005-05-26 The Board Of Trustees Of The University Of Illinois Induction of cellular senescence by cdk4 disruption for tumor suppression and regression
SE0303397D0 (sv) * 2003-12-17 2003-12-17 Index Pharmaceuticals Ab Compounds and method for RNA interference
ATE491715T1 (de) 2004-01-30 2011-01-15 Quark Pharmaceuticals Inc Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
EP1718747B1 (en) * 2004-02-06 2009-10-28 Dharmacon, Inc. Stabilized rnas as transfection controls and silencing reagents
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
EP2636739B1 (en) 2004-03-12 2014-12-10 Alnylam Pharmaceuticals Inc. iRNA agents targeting VEGF
JPWO2005087269A1 (ja) * 2004-03-16 2008-01-24 株式会社ディナベック研究所 腫瘍増殖を抑制する方法
EP1735442A2 (en) * 2004-03-24 2006-12-27 Oncotherapy Science, Inc. Compositions and methods for treating pancreatic cancer
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
EP2495324B1 (en) 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
DE112004002914A5 (de) * 2004-05-06 2007-05-24 Medizinische Hochschule Hannover Verbindungen und Verfahren zur Immunsuppression
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
AU2005243410B2 (en) 2004-05-14 2010-04-22 Rosetta Genomics Ltd. Micronas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
PL1791568T3 (pl) 2004-08-16 2013-01-31 Quark Pharmaceuticals Inc Terapeutyczne zastosowania inhibitorów RTP801
SI1781787T1 (sl) 2004-08-23 2017-08-31 Sylentis S.A.U. Zdravljenje očesnih nepravilnosti, kakakterističnih za povišan očesni tlak s sirna
WO2006024880A2 (en) * 2004-08-31 2006-03-09 Sylentis S.A.U. Methods and compositions to inhibit p2x7 receptor expression
CN102643818B (zh) 2004-09-28 2014-04-09 夸克制药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
WO2006039806A1 (en) * 2004-10-14 2006-04-20 Institut De Cardiologie De Montreal Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
US7595159B2 (en) 2004-11-03 2009-09-29 The Brigham And Women's Hospital, Inc. Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
KR100780548B1 (ko) 2004-12-08 2007-11-29 한국원자력연구원 S-아데노실 메티오닌 디카르복실라제 mRNA에특이적인 작은 간섭 RNA 및 그를 유효성분으로포함하는 악성종양 치료제
US8003619B2 (en) 2004-12-09 2011-08-23 Alnylam Pharmaceuticals, Inc. Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
AU2011203218B2 (en) * 2004-12-09 2013-02-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
DE602005027747D1 (de) * 2004-12-22 2011-06-09 Alnylam Pharmaceuticals Inc Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
EP1830888B1 (en) 2004-12-27 2015-08-05 Silence Therapeutics GmbH Lipid complexes coated with peg and their use
US8227591B2 (en) * 2005-03-02 2012-07-24 National Institute Of Immunology Nucleotide sequences
GB0505081D0 (en) 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
JP4982757B2 (ja) * 2005-04-15 2012-07-25 国立大学法人鳥取大学 hTERT発現調節遺伝子
KR20060119412A (ko) * 2005-05-20 2006-11-24 아주대학교산학협력단 IL-6 발현 억제를 위한 siRNA 및 이를 함유하는조성물
JP5176104B2 (ja) * 2005-07-15 2013-04-03 国立大学法人名古屋大学 エレクトロポレーション装置の制御方法
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
NZ565712A (en) * 2005-08-17 2011-09-30 Sirna Therapeutics Inc Chemically modified short interfering nucleic acid molecules that mediate RNA interface
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
US20080090775A1 (en) * 2005-10-31 2008-04-17 Chong Huang Antagonist of TEB4 and Methods of Use
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
PL1966368T3 (pl) * 2005-12-29 2013-03-29 Alcon Res Ltd Hamowanie IGF-1R za pośrednictwem RNAi do leczenia angiogenezy
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
JP5244087B2 (ja) 2006-03-23 2013-07-24 サンタリス ファーマ アー/エス 低分子内部セグメント化干渉rna
EP2007888A2 (en) * 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8399424B2 (en) 2006-06-08 2013-03-19 Amino Up Chemical Co., Ltd Method for controlling the amount of gene product, and agent for controlling the amount of gene product
KR20090018859A (ko) 2006-06-08 2009-02-23 가부시키가이샤 아미노 압 가가쿠 iNOS의 발현 제어 작용을 갖는 센스 올리고뉴클레오티드 및 그것을 포함하는 조성물
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc THERAPEUTIC USES OF RTP801L INHIBITORS
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CA2662843A1 (en) * 2006-09-07 2008-03-13 Universidad De Salamanca Identification of cancer stem cells using genetic markers
US9074205B2 (en) * 2006-10-18 2015-07-07 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
EP2468886A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
WO2008109359A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof
WO2008109378A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
WO2008109454A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting fos gene expression and uses thereof
WO2008109492A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 1本鎖環状rnaおよびその製造方法
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
WO2009021150A2 (en) * 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
BRPI0816150A2 (pt) 2007-08-24 2019-09-24 Oncotherapy Science Inc genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
BRPI0815757A2 (pt) 2007-08-24 2015-02-18 Oncotherapy Science Inc Os genes pkib e naalad2 como alvos do tratamento e do diagnóstico do câncer de próstata
WO2009039173A2 (en) 2007-09-19 2009-03-26 Applied Biosystems Inc. SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
ES2647538T3 (es) 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
EP2231168A4 (en) * 2007-10-03 2012-01-04 Quark Pharmaceuticals Inc NEW STRUCTURES OF ARNSI
JP2011504730A (ja) * 2007-11-29 2011-02-17 蘇州瑞博生物技術有限公司 標的遺伝子の発現を干渉する複合体分子およびその合成方法
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
CA3069576A1 (en) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
JP5346957B2 (ja) 2008-01-23 2013-11-20 ヘルレフ ホスピタル 不特定疾患の汎用マーカーとしてのykl−40
JP5906508B2 (ja) * 2008-03-31 2016-04-20 国立研究開発法人産業技術総合研究所 Rna干渉効果が高い2本鎖脂質修飾rna
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US8278287B2 (en) 2008-04-15 2012-10-02 Quark Pharmaceuticals Inc. siRNA compounds for inhibiting NRF2
AU2009236219B8 (en) 2008-04-15 2015-06-25 Arbutus Biopharma Corporation Silencing of CSN5 gene expression using interfering RNA
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
WO2009131733A1 (en) * 2008-04-21 2009-10-29 The Trustees Of Columbia University In The City Of New York Gab2 amplification in melanoma
JP5524189B2 (ja) 2008-06-06 2014-06-18 クォーク ファーマシューティカルズ インコーポレーティッド 耳障害治療のための組成物および方法
US8309791B2 (en) 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon
WO2010023877A1 (en) 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Prmt1 for target genes of cancer therapy and diagnosis
JP2012502285A (ja) 2008-09-15 2012-01-26 ヘルレフ ホスピタル 消化管癌のマーカーとしてのykl−40
JP2011251912A (ja) * 2008-09-22 2011-12-15 Gifu Prefecture Kenkyu Kaihatsu Zaidan マイクロrna―143誘導体を含有する医薬
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
CN102612560B (zh) * 2009-06-16 2017-10-17 库尔纳公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
CA2775092A1 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
US8796239B2 (en) 2009-11-26 2014-08-05 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN101787366B (zh) * 2010-03-04 2012-09-19 中国人民解放军军事医学科学院放射与辐射医学研究所 一种特异抑制Rab27B基因表达的DNA片段及其应用
EP2598639A4 (en) 2010-07-28 2014-08-13 Alcon Res Ltd SIRNA TARGETED VEGFA AND IN VIVO TREATMENT PROCESS WITH THIS
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP3372684B1 (en) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Single-stranded rnai agents containing an internal, non-nucleic acid spacer
EP2611933A1 (en) * 2010-09-02 2013-07-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of the progression of cancer
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2638912A4 (en) 2010-11-12 2015-01-21 Nat Univ Corp Ehime Univ COMPOSITIONS WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST MICRO RNA
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2013003346A2 (en) * 2011-06-27 2013-01-03 Medimmune, Llc Microrna-31 compositions and methods for use in autoimmune disease
DK2726613T3 (en) 2011-06-30 2018-12-03 Arrowhead Pharmaceuticals Inc COMPOSITIONS AND PROCEDURES FOR INHIBITING GENEPRESSION OF HEPATITIS B VIRUS
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
US20140243391A1 (en) 2011-07-22 2014-08-28 Centre National De La Recherche Scientifique Phospholipid-detergent conjugates and uses thereof
EP2776450B1 (en) * 2011-11-10 2018-04-04 Shire Human Genetic Therapies, Inc. Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof
JP6268097B2 (ja) 2011-11-11 2018-01-24 デューク・ユニヴァーシティ 固形腫瘍治療のための併用薬物療法
CA2856289A1 (en) * 2011-11-18 2013-05-23 Alnylam Pharmaceuticals, Inc. Modified rnai agents
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
US11180760B2 (en) * 2012-03-09 2021-11-23 The Johns Hopkins University Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
TWI480043B (zh) * 2012-05-01 2015-04-11 Univ Kaohsiung Medical 用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2013177194A1 (en) * 2012-05-22 2013-11-28 University Of Massachusetts Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
WO2013192233A1 (en) * 2012-06-18 2013-12-27 Isis Pharmaceuticals, Inc. Compounds and method for improved cellular uptake of antisense compounds
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
EP2700949A1 (en) 2012-08-24 2014-02-26 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Use of biliverdin reductase proteins as cancer marker
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
BR112015004452A2 (pt) 2012-09-05 2017-08-08 Sylentis Sau sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
EP2892568B1 (en) * 2012-09-06 2020-08-26 Health Research, Inc. Compositions and methods for inhibiting hypoxia induced damage
EP4163387A1 (en) 2013-03-15 2023-04-12 The University of Chicago Methods and compositions related to t-cell activity
CN105324392A (zh) 2013-04-20 2016-02-10 全国儿童医院研究所 外显子2靶向U7snRNA多核苷酸构建体的重组腺相关病毒递送
EP3003290B1 (en) 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
KR20160095003A (ko) 2013-12-05 2016-08-10 사일런스 테라퓨틱스 게엠베하 폐 특이적 전달을 위한 수단
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
SI3145934T1 (sl) 2014-05-19 2021-04-30 Pfizer Inc. Substituirane spojine -6,8-dioksabiciklo(3.2.1)oktan-2,3-diol kot zdravila, ki delujejo na ASGPR
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
EP3172324A4 (en) 2014-07-18 2018-04-25 Oregon Health & Science University 5'-triphosphate oligoribonucleotides
EP3180435A4 (en) 2014-08-09 2018-01-17 The Research Institute at Nationwide Children's Hospital Methods and materials for activating an internal ribosomal entry site in exon 5 of the dmd gene
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CA2965696A1 (en) 2014-11-12 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of hormonal disorders of growth
RU2563989C1 (ru) * 2014-11-20 2015-09-27 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Композиция для подавления экспрессии гена цитокина интерлейкина-4
US10130651B2 (en) 2015-08-07 2018-11-20 Arrowhead Pharmaceuticals, Inc. RNAi Therapy for Hepatitis B Virus Infection
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
US20190242875A1 (en) * 2016-05-10 2019-08-08 National University Corporation Tokyo Medical And Dental University Expression Inhibitor of Inflammation Promoting Factor, Screening Method for Active Ingredient Thereof, Expression Cassette Useful for Said Method, Diagnostic Agent and Diagnosis Method
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
EP3269732A1 (en) * 2016-07-11 2018-01-17 Rhemastem SRLS Therapeutic medium for the treatment of cancer
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018107096A1 (en) * 2016-12-08 2018-06-14 University Of Utah Research Foundation Staufen1 agents and associated methods
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
KR102675026B1 (ko) 2017-01-10 2024-06-17 애로우헤드 파마슈티컬스 인코포레이티드 알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US20200038429A1 (en) * 2017-04-19 2020-02-06 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
CA3057974A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
CA3066959A1 (en) 2017-06-16 2018-12-20 Imba - Institut Fur Molekulare Biotechnologie Gmbh Blood vessel organoid, methods of producing and using said organoids
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
KR102715821B1 (ko) 2017-11-09 2024-10-10 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법
IL274906B1 (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods of treating muscle atrophy and myotonic dystrophy
WO2019168897A2 (en) * 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US20210009711A1 (en) * 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3807291A4 (en) 2018-06-14 2022-02-23 University of Utah Research Foundation STAUFEN1 REGULATING AGENTS AND RELATED METHODS
CN108977445B (zh) * 2018-06-29 2021-05-25 山东农业大学 拟南芥microRNA400在调控植物耐镉性中的应用
WO2020011653A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011743A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mafb
US10857174B2 (en) 2018-07-27 2020-12-08 United States Government As Represented By The Department Of Veterans Affairs Morpholino oligonucleotides useful in cancer treatment
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3833397A4 (en) * 2018-08-08 2023-06-14 Arcturus Therapeutics, Inc. COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
CN119265191A (zh) 2018-08-13 2025-01-07 阿尔尼拉姆医药品有限公司 乙型肝炎病毒(HBV)dsRNA剂组合物及其使用方法
KR102097794B1 (ko) * 2018-09-17 2020-04-06 차의과학대학교 산학협력단 신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
WO2020225779A1 (en) 2019-05-09 2020-11-12 Istituto Pasteur Italia - Fondazione Cenci Bolognetti Rig-i agonists for cancer treatment and immunotherapy
US20230150926A1 (en) 2020-03-17 2023-05-18 Genevant Sciences Gmbh Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
US11525137B2 (en) 2020-03-19 2022-12-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
AU2021241682A1 (en) 2020-03-27 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
US20240148663A1 (en) 2020-12-18 2024-05-09 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
IL311452A (en) 2021-09-16 2024-05-01 Avidity Biosciences Inc Compositions and methods for the treatment of FSHD muscular dystrophy
JP2025504682A (ja) 2022-01-31 2025-02-14 ジェネバント サイエンシズ ゲーエムベーハー ポリ(アルキルオキサゾリン)-脂質コンジュゲートおよびそれを含む脂質粒子
EP4466250B1 (en) 2022-01-31 2025-03-26 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
EP4499834A2 (en) 2022-03-28 2025-02-05 Empirico Inc. Modified oligonucleotides
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2024159113A1 (en) * 2023-01-27 2024-08-02 The Methodist Hospital Modulators of alternative polyadenylation and methods of use thereof
WO2024215814A2 (en) * 2023-04-10 2024-10-17 Anand Rene Methods and pharmaceutical compositions for treating aging
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012244B2 (ja) 1987-09-21 2000-02-21 ジェン―プローブ インコーポレイテッド ヌクレオチドプローブ用非ヌクレオチド連結試薬
WO1990014090A1 (en) * 1989-05-19 1990-11-29 Hem Research, Inc. SHORT THERAPEUTIC dsRNA OF DEFINED STRUCTURE
AU637800B2 (en) 1989-08-31 1993-06-10 City Of Hope Chimeric dna-rna catalytic sequences
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー.ファウ. 修飾リボザイム
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
EP1695979B1 (en) * 1991-12-24 2011-07-06 Isis Pharmaceuticals, Inc. Gapped modified oligonucleotides
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US20030125270A1 (en) 2000-12-18 2003-07-03 Lawrence Blatt Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
CA2139319A1 (en) * 1992-07-02 1994-01-20 Sudhir Agrawal Self-stabilized oligonucleotides as therapeutic agents
CA2140343A1 (en) 1992-07-17 1994-02-03 Sean M. Sullivan Method and reagent for treatment of animal diseases
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
JPH08505872A (ja) 1993-01-22 1996-06-25 ユニバーシティ・リサーチ・コーポレイション 治療剤の局所化
ATE258596T1 (de) * 1993-07-10 2004-02-15 Biognostik Ges Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
DE69431669T2 (de) 1993-09-02 2003-10-23 Ribozyme Pharmaceuticals, Inc. Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5990090A (en) * 1993-09-20 1999-11-23 The University Of Michigan Methods and compositions for treatment of diseases
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
DK0725788T3 (da) 1993-10-27 1999-08-23 Ribozyme Pharm Inc 2'-amido- og 2'-peptidomodificerede oligonukleotider
WO1995022600A1 (en) * 1994-02-22 1995-08-24 Immusol, Inc. Ribozyme therapy for hepatitis b infection
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
AU4412096A (en) 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
WO2002096927A2 (en) * 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
EP0866865B1 (en) * 1995-11-14 2002-02-06 Vimrx Holdings, Ltd. Chimeric oligomers having an rna-cleavage activity
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
AU1430097A (en) 1996-01-16 1997-08-11 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
CA2281903A1 (en) * 1997-03-28 1998-10-08 The Research Foundation Of State University Of New York Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
JP2001510808A (ja) * 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
KR20010030622A (ko) * 1997-09-17 2001-04-16 리차드 알. 이킨 다중 표적 하이브리드형성 핵산과 그들의 제조, 구성,제제, 키트 및 응용
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
CA2228977A1 (en) * 1997-11-07 1999-05-07 Martin G. Sirois Localized oligonucleotide therapy for preventing restenosis
US5932580A (en) * 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
PL343064A1 (en) 1998-03-20 2001-07-30 Benitec Australia Ltd Control of gene expression
DK1068311T3 (da) 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
WO1999054459A2 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE69926007T2 (de) * 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
AU774266B2 (en) * 1998-10-09 2004-06-24 Vegenics Limited Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6069008A (en) * 1998-11-25 2000-05-30 Isis Pharmaceuticals Inc. Antisense modulation of NF-kappa-B p65 subunit expression
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU3369900A (en) * 1999-02-19 2000-09-04 General Hospital Corporation, The Gene silencing
US5998206A (en) * 1999-02-23 1999-12-07 Isis Pharmaceuticals Inc. Antisense inhibiton of human G-alpha-12 expression
MXPA01009073A (es) 1999-03-10 2002-05-06 Phogen Ltd Suministro de acidos nucleicos y proteinas a las celulas.
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
DE60033927T2 (de) 1999-05-04 2007-11-29 Santaris Pharma A/S L-ribo-lna analoge
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
EP1194556A1 (en) 1999-07-09 2002-04-10 American Home Products Corporation Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence
US20040002153A1 (en) * 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
AUPQ201499A0 (en) * 1999-08-04 1999-08-26 Unisearch Limited Treatment of inflammatory and malignant diseases
ATE338139T1 (de) * 1999-08-30 2006-09-15 Wisconsin Alumni Res Found Herstellung von 3-hydroxypropionsäure in rekombinanten organismen
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2001038551A1 (en) 1999-11-29 2001-05-31 Cold Spring Harbor Laboratory Regulation of polycomb group gene expression for increasing seed size in plants
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
WO2001049844A1 (en) 1999-12-30 2001-07-12 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
IT1316982B1 (it) 2000-01-17 2003-05-26 Univ Roma Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi.
US6602857B1 (en) * 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
IL151781A0 (en) * 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
GB2377221B (en) 2000-03-17 2004-08-18 Benitec Australia Ltd Genetic silencing
WO2001070944A2 (de) 2000-03-22 2001-09-27 Aventis Pharma Deutschland Gmbh Nematoden als modellorganismen zur untersuchung neurodegenerativer erkrankungen und insbesonder der parkinsonschen erkrankung, verwendungen und verfahren zum auffinden von substanzen und genen, die bei der behandlung solcher erfrankungen eingesetz werden können, sowie identifizierung eines nematodengens.
GB0007268D0 (en) 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins
KR101215789B1 (ko) 2000-03-30 2012-12-26 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
EP1290161B1 (en) 2000-05-30 2011-06-22 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
JP2004512022A (ja) * 2000-06-09 2004-04-22 コリクサ コーポレイション 結腸癌の治療および診断のための組成物および方法
WO2001096584A2 (en) * 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
ES2287152T3 (es) * 2000-06-23 2007-12-16 Bayer Schering Pharma Aktiengesellschaft Combinaciones y composiciones que interfieren con la funcion de vegf/receptor vegf y angiopoyetina/receptor tie, y su utilizacion (ii).
US7175844B2 (en) * 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US6613567B1 (en) * 2000-09-15 2003-09-02 Isis Pharmaceuticals, Inc. Antisense inhibition of Her-2 expression
US7312325B2 (en) * 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
JP2002117576A (ja) * 2000-10-03 2002-04-19 Tdk Corp 光記録媒体および光学的情報記録方法
AU2002246627A1 (en) * 2000-10-26 2002-08-06 Beth Israel Deaconess Medical Center, Inc. Gab2(p97) gene and methods of use thereof
DE60135482D1 (de) 2000-11-09 2008-10-02 Cenix Bioscience Gmbh Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
DK1407044T4 (en) 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
EP1233059A1 (en) * 2001-02-09 2002-08-21 ARTEMIS Pharmaceuticals GmbH Influenza viruses with enhanced transcriptional and replicational capacities
US20030087855A1 (en) 2001-09-13 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase R expression
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
EP2364990A1 (en) 2001-05-25 2011-09-14 Duke University Modulators of pharmacological agents
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7820632B2 (en) * 2002-02-14 2010-10-26 City Of Hope Methods for producing interfering RNA molecules in mammalian cells and therapeutic uses for such molecules
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
US7399586B2 (en) * 2002-05-23 2008-07-15 Ceptyr, Inc. Modulation of biological signal transduction by RNA interference
AU2003237686A1 (en) * 2002-05-24 2003-12-12 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
CA2388441A1 (en) * 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
SI2258847T1 (sl) 2002-08-05 2017-08-31 Silence Therapeutics Gmbh Nadaljnje nove oblike molekul interferenčne RNA
DK1389637T3 (da) * 2002-08-05 2012-09-03 Silence Therapeutics Ag Interfererende RNA-molekyler med stumpe ender
WO2004029212A2 (en) * 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
AU2004210972A1 (en) * 2003-02-11 2004-08-26 Immusol Incorporated siRNA libraries optimized for predetermined protein families
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
US8240498B2 (en) 2006-10-31 2012-08-14 Crown Packaging Technology, Inc. Resealable closure
EP3305229A4 (en) 2015-06-01 2019-02-20 Olympus Corporation MEDICAL MANIPULATOR

Also Published As

Publication number Publication date
EP1458741B1 (en) 2012-10-17
EP2287305A1 (en) 2011-02-23
EP1458741A4 (en) 2005-09-14
EP2278004A1 (en) 2011-01-26
EP3926046A2 (en) 2021-12-22
EP2902406B1 (en) 2018-01-31
EP1432724A1 (en) 2004-06-30
ES2667672T3 (es) 2018-05-14
SI2287305T1 (sl) 2015-05-29
DK2287305T4 (en) 2018-02-05
AU2003247204A8 (en) 2003-09-09
EP1549660A2 (en) 2005-07-06
PT2902406T (pt) 2018-05-22
WO2003074654A2 (en) 2003-09-12
AU2003216315A1 (en) 2003-09-09
EP1470256A2 (en) 2004-10-27
WO2003070911A2 (en) 2003-08-28
GB0406022D0 (en) 2004-04-21
EP1423406A4 (en) 2005-05-04
EP1476574A4 (en) 2005-05-04
WO2003070970A2 (en) 2003-08-28
WO2003070968A3 (en) 2004-02-12
EP1476458A4 (en) 2005-05-04
EP3926046A3 (en) 2022-03-23
EP3354656A1 (en) 2018-08-01
HUE036869T2 (hu) 2018-08-28
CA2459532A1 (en) 2003-08-28
AU2003207708A1 (en) 2003-09-09
EP1470256A4 (en) 2006-01-25
DK2902406T3 (en) 2018-04-16
EP2287305B2 (en) 2017-11-29
EP1472269A4 (en) 2005-03-23
AU2003217594A8 (en) 2003-09-09
WO2003074654A3 (en) 2004-02-05
JP2008289488A (ja) 2008-12-04
EP2042510A2 (en) 2009-04-01
EP1472269A1 (en) 2004-11-03
AU2010212416B2 (en) 2011-10-20
AU2003219712A1 (en) 2003-09-09
CA2476112A1 (en) 2003-08-28
GB2397818B (en) 2005-03-09
HK1065049A1 (en) 2005-02-08
GB2396616A (en) 2004-06-30
AU2003219712A8 (en) 2003-09-09
AU2003216324A1 (en) 2003-09-16
AU2003217594A1 (en) 2003-09-09
DK2287306T3 (da) 2012-12-17
CA2455447A1 (en) 2003-09-12
EP2287306B1 (en) 2012-08-22
EP1423406A2 (en) 2004-06-02
WO2003070914A3 (en) 2003-12-24
WO2003070914A2 (en) 2003-08-28
AU2003213163A1 (en) 2003-09-09
EP3354656B1 (en) 2021-04-07
AU2010212416A1 (en) 2010-09-09
JP2005517438A (ja) 2005-06-16
EP1423406B2 (en) 2015-11-25
ES2394269T3 (es) 2013-01-30
WO2003070903A3 (en) 2005-05-12
EP1476458A2 (en) 2004-11-17
GB2397818A (en) 2004-08-04
WO2003070886A2 (en) 2003-08-28
EP2287305B1 (en) 2015-01-07
WO2003070970A3 (en) 2004-06-10
AU2003219751A8 (en) 2003-09-09
AU2003216311A8 (en) 2003-09-09
JP2006271387A (ja) 2006-10-12
EP2042510A3 (en) 2009-06-24
EP2287306A1 (en) 2011-02-23
SI2902406T1 (sl) 2018-06-29
AU2003247204A1 (en) 2003-09-09
WO2003070903A2 (en) 2003-08-28
CY1120292T1 (el) 2019-07-10
EP1423406B1 (en) 2010-09-01
EP3459963A1 (en) 2019-03-27
DK1423406T3 (da) 2011-01-10
WO2003070968A2 (en) 2003-08-28
WO2003070886A3 (en) 2004-04-01
AU2003211082A1 (en) 2003-09-09
WO2003072704A3 (en) 2003-12-31
AU2003219751A1 (en) 2003-09-09
EP1476574A2 (en) 2004-11-17
PT2287305E (pt) 2015-04-20
EP2287306B2 (en) 2016-10-12
AU2003213163A8 (en) 2003-09-09
WO2003070744A1 (en) 2003-08-28
WO2003072704A2 (en) 2003-09-04
WO2003070911A3 (en) 2004-08-26
AU2003216315A8 (en) 2003-09-09
JP2005518803A (ja) 2005-06-30
AU2003221258B2 (en) 2006-05-25
GB0404912D0 (en) 2004-04-07
GB2396616B (en) 2005-09-21
AU2003216311A1 (en) 2003-09-09
EP2278004B1 (en) 2012-10-31
EP1549660A4 (en) 2006-03-22
CY1117168T1 (el) 2017-04-05
EP1472267A4 (en) 2005-11-09
US8648185B2 (en) 2014-02-11
ES2534045T5 (es) 2018-03-20
EP1458741A2 (en) 2004-09-22
EP1470257A4 (en) 2005-03-16
JP2009060893A (ja) 2009-03-26
EP1470257A2 (en) 2004-10-27
US20130012567A1 (en) 2013-01-10
AU2003216324B2 (en) 2009-02-26
EP1472267A2 (en) 2004-11-03
EP2902406A1 (en) 2015-08-05
AU2003221258A1 (en) 2003-09-09
JP2005524393A (ja) 2005-08-18
DK2287305T3 (en) 2015-03-09
US20090023676A1 (en) 2009-01-22
EP1432724A4 (en) 2006-02-01
ATE479774T1 (de) 2010-09-15
ES2534045T3 (es) 2015-04-16

Similar Documents

Publication Publication Date Title
SI2287305T2 (sl) Z rna-interferenco posredovano inhibiranje izražanja gena z uporabo male interferenčne nukleinske kisline (sina)
CA2526831A1 (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JP2006502694A5 (sl)
US8497364B2 (en) Triggered RNAi
JP2005517452A5 (sl)
US20080214488A1 (en) TRIGGERED RNAi
JP2005517427A5 (sl)
WO2003070193A3 (en) RNA interference mediated inhibition of HIV gene expression using short interfering nucleic acid (siNA)
Pasternak et al. Unlocked nucleic acid–an RNA modification with broad potential
JP2015221042A (ja) 修飾を有するdsRNAによる遺伝子発現の特異的な阻害のための組成物および方法
JP2005517430A5 (sl)
JP2005524393A5 (sl)
US20240296903A1 (en) Methods of placing locked nucleic acids in small interfering rna strands
WO2003070888B1 (en) Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
WO2003070197A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1710307A3 (en) RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
JP7216381B2 (ja) Rna作用抑制剤及びその利用
WO2024154163A1 (en) Product comprising an aptamer conjugated to the edited mirna mir-589-3p and medical uses thereof
CN101824063A (zh) 一种用烷基修饰的核酸及其修饰方法和应用